Accelerating genetic progress

During the year, progress against our strategic objectives included:

• Continuing to develop our range of industry-leading genetics and beginning to assimilate genes acquired from Hermitage Genetics
• Collaborating with R&D colleagues and external partners on long-term development programmes, including our investigational gene-editing project to produce animals resistant to PRRSv

• Increasing our share of business with large producers around the world, so we now work with over 70% of the largest global accounts
• Maintaining our progress in Europe (achieving growth of 26% and continuing to see the benefits of our tailored strategy for China (with growth of 82%)
• Strengthening our supply chain to support markets around the world by upgrading several sites and incorporating Hermitage Genetics facilities

• Conducting 26 product trials across seven countries, involving more than 63,000 pigs, demonstrating the difference our products and services deliver for customers
• Expanding use of the royalty pricing model, particularly in Europe and Asia (including further contracts in China), so that 77% of our volumes are now conducted on a royalty basis

• Continuing to implement our global strategy, tailored to local markets where needed

• Expanding use of the royalty model where possible, particularly accelerating the transition in China

• Making further investments in our supply chain to underpin growth

• Continuing to collaborate with colleagues and partners on new technologies and on plans to commercialise and achieve regulatory acceptance for gene-edited animals